FPL-62129

CAS No. 95445-79-7

FPL-62129( —— )

Catalog No. M34260 CAS No. 95445-79-7

FPL-62129 is a calcium channel antagonist and a novel angiotensin-converting enzyme inhibitor with vasodilator activity for the study of cardiovascular disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 411 In Stock
10MG 562 In Stock
25MG 866 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    FPL-62129
  • Note
    Research use only, not for human use.
  • Brief Description
    FPL-62129 is a calcium channel antagonist and a novel angiotensin-converting enzyme inhibitor with vasodilator activity for the study of cardiovascular disease.
  • Description
    FPL-62129 is a calcium channel antagonist and a novel angiotensin-converting enzyme inhibitor with vasodilator activity for the study of cardiovascular disease.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    RAAS
  • Recptor
    RAAS | Calcium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    95445-79-7
  • Formula Weight
    467.81
  • Molecular Formula
    C20H19ClF5NO4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC)C1=C(NC(=C(C(=O)OC(C)C)C1C=2C(F)=CC=C(Cl)C2C(F)(F)F)C)CF
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • L-162,313

    L-162,313 is an ANG II receptor agonist, a nonpeptide that mimics the biological actions of angiotensin II and induces an increase in MAP.

  • Buloxibutid

    Buloxibutid (AT2 receptor agonist C21) is a novel and selective small molecule angiotensin II AT2 receptor agonist, exhibiting Ki values of 0.4 nM and 10 μM for AT2 and AT1 receptors, respectively.

  • YS-49

    YS-49 is an activator of PI3K/Akt (a downstream target of RhoA).